Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial of fibromyalgia patients, CBD did not demonstrate superiority over placebo in reducing pain. These findings suggest that the widespread clinical use of CBD for fibromyalgia pain lacks robust trial-level support. Patients and clinicians should interpret current CBD recommendations for fibromyalgia with caution until larger, confirmatory studies are available.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomised controlled trial provides rigorous evidence to address the widespread clinical use of CBD in fibromyalgia patients, where current therapeutic options remain limited and efficacy data are sparse. The findings will inform whether CBD represents a viable pharmacological alternative for fibromyalgia pain management or whether its use lacks adequate evidence-based justification. Given the prevalence of fibromyalgia and patients’ frequent off-label cannabinoid use, establishing CBD’s true efficacy through this rigorous design is essential for evidence-based prescribing guidance.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This randomized controlled trial addresses a significant evidence gap by rigorously testing cannabidiol against placebo in fibromyalgia patients, a population that often pursues cannabis-based therapies with limited clinical validation. While the study design is methodologically sound with its double-blind, placebo-controlled approach, the single-center Danish recruitment and relatively small sample size may limit generalizability to diverse fibromyalgia populations across different geographic and healthcare settings. The results should be interpreted cautiously given fibromyalgia’s notable placebo responsiveness and the heterogeneity in CBD formulations, dosing regimens, and individual patient factors that influence cannabinoid metabolism and efficacy. Clinically, this trial provides a foundation for informed conversations with fibromyalgia patients considering CBD, allowing us to acknowledge both the biological plausibility of cannabinoid analgesia and the current modest evidence base, while emphasizing the importance of individualized assessment, close monitoring, and integration with established multimodal pain management strategies rather than